Developing a Respiratory Drug for:

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Bronchitis

Emphysema

Cystic Fibrosis (CF)

Interstitial Lung Disease (ILD)

Regulation of Nitric Oxide (NO)

Sodium Pyruvate

Phase I/II Study of Mild Asthmatics

Phase I/II Nitric Oxide (NO) Study

Phase I/II Study in Severe COPD Patients

Phase I/II Double Blinded Placebo Controlled Study in Severe COPD Patients

Anti-Viral Effects of Nitric Oxide (NO)

Pyruvate in Cancer Prevention & Treatment

Sarcoidosis


Welcome to EmphyCorp.com

EmphyCorp is developing a proprietary new technology, N115, for the treatment of pulmonary diseases.

N115 facilitates the healing process, enabling the lungs and bronchial tubes to repair themselves. Increased pulmonary function and neutralization of oxygen radicals can often be seen within minutes. N115 is a safe, low molecular weight molecule.

The ability of inhaled alpha keto acids, including sodium pyruvate to "up regulate" or "down regulate" nitric oxide (NO) levels in the lungs, and to protect nitric oxide (NO) from being destroyed by hydrogen peroxide and other oxygen radicals, will reduce lung inflammation and allow nitric oxide to function normally in the lungs. Nitric oxide (NO) is also used by the human body to kill bacterial infections, fungal infections, viral infections and tumors.

It is expected that N115 will become a "first choice" treatment for asthmas, COPD, Inflammatory Lung Diseases, Emphysema, Bronchitis, Cystic Fibrosis, and various other pulmonary diseases. Based on current clinical findings, N115 should be safe and effective in the treatment of major pulmonary diseases.

More about N115 >

Latest EmphyCorp News

March 2, 2007
EmphyCorp Phase I/II Human Clinical Data and Regulation of Lung Nitric Oxide Levels

April 1, 2004
EmphyCorp Granted Sixth U.S. Respiratory Patent

More news >



The FDA has determined that N115 has sufficient safety toxicology and clinical data to proceed with the multi-dose, extended use, clinical trials. Phase II studies will focus on asthmatics and COPD patients. On the basis of existing clinical data, EmphyCorp is confident that its Investigative New Drug, N115, can and will be used for maintenance or continuous treatment of patients over extended periods of time. The Company believes that N115 will set the standard in the pharmaceutical industry for the treatment of major pulmonary diseases.

Home | News | About EmphyCorp | About N115 | N115 Patents | About Lung Diseases | The Market | Contact Us

Site by 2Profound.com